Healing the Gun Violence Epidemic through Health System Action - NEJM Catalyst Innovations in Care Delivery

IntroductionEarly warning has long been regarded as a cornerstone of infectious disease surveillance and epidemic preparedness1,2. Substantial advances in epidemiological modeling, statistical inference, and data integration have improved outbreak detection and disease forecasting across diverse settings over recent decades3. Major public health emergencies, including SARS, influenza pandemics, COVID-19, and more recent emerging infectious diseases, have benefited from these developments in situational awareness4,5,6. Recent global health crises have, however, revealed a persistent limitation that we term the decision gap: technically sophisticated forecasts and risk indicators frequently fail to translate into timely, coordinated, context-sensitive action7,8,9. This gap has two linked faces: (1) Forecasts are often not decision-ready: they do not encode operational constraints, competing objectives, or uncertainty in usable form. (2) Institutions must still convert uncertain, evolving evidence into action through deliberation under legal and organizational constraints, a process current systems leave largely unsupported. This gap is not hypothetical.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.